{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:41:15Z","timestamp":1794361275149,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ixekizumab (IXE), an IL-17\u00a0A inhibitor, demonstrated efficacy in clinical trials in patients with psoriatic arthritis (PsA), and favorable data have emerged from real-world evidence studies on psoriasis as well. However, real-world data specific to PsA remain limited. This study aims to assess IXE effectiveness in reducing disease activity in patients with PsA and determine its drug retention rate (DRR) over 24 months. The secondary aim is to identify factors potentially affecting long-term persistence on therapy. A retrospective observational study was conducted. Consecutive adult patients meeting the CASPAR criteria for PsA and treated with IXE for \u2265\u20093 months were included. Patients were evaluated at regular intervals on a routine clinical basis for disease activity and quality of life assessment. 132 patients (78 females, 54 males; mean age 59.1\u2009\u00b1\u200911.9 years) were included. At baseline, the median (IQR) Disease Activity in Psoriatic Arthritis (DAPSA) was 16.2 (7.7), and the visual analogue scale (VAS) for pain was 6.5 (3.0). In patients with axial involvement, the median (IQR) Ankylosing Spondylitis Disease Activity Score \u2013 C-reactive protein (ASDAS-CRP) was 3.4 (1.3), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 5.0 (1.5). IXE treatment was associated with statistically significant reductions in DAPSA (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), ASDAS-CRP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), BASDAI (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), VAS-pain (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), Health Assessment Questionnaire (HAQ) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), erythrocyte sedimentation rate (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014), and CRP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) over 24 months. At 24 months, remission and low disease activity, according to DAPSA thresholds, were achieved by 46.7% and 93.3% of patients, respectively, while Very Low Disease Activity and Minimal Disease Activity criteria were met by 16.0% and 34.0%, respectively. IXE DRR was 82.1%, 76.3%, and 73.3% at 12, 18, and 24 months, respectively, with lower values in female patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.036). No differences were observed in IXE DRR when stratifying the cohort by axial involvement (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.84), prior exposure to biologics or tsDMARDs (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.68), or body mass index (BMI) categories (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.48). In conclusion, IXE enabled rapid and sustained disease control in patients with PsA across multiple disease domains. The high DRR supports its long-term use, regardless of prior biologic exposure or BMI. Gender differences in IXE treatment response may warrant further exploration.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-37835-x","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:19:51Z","timestamp":1771499991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study"],"prefix":"10.1038","volume":"16","author":[{"given":"Stefano","family":"Gentileschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Terribili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-8343","authenticated-orcid":false,"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cometi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Cigolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scriffignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Cato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Li Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Delle Sedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"37835_CR1","unstructured":"Tiwari, V. & Brent, L. H. Psoriatic Arthritis. StatPearls Publishing (2024)."},{"key":"37835_CR2","doi-asserted-by":"publisher","first-page":"737079","DOI":"10.3389\/fmed.2021.737079","volume":"8","author":"L Novelli","year":"2021","unstructured":"Novelli, L. et al. Extra-Articular manifestations and comorbidities in psoriatic disease: A journey into the Immunologic crosstalk. Front. Med. (Lausanne). 8, 737079 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"37835_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3899\/jrheum.190054","volume":"46","author":"E Lubrano","year":"2019","unstructured":"Lubrano, E., Scriffignano, S. & Perrotta, F. M. Psoriatic Arthritis, psoriatic Disease, or psoriatic syndrome? J. Rheumatol. 46, 1428\u20131430 (2019).","journal-title":"J. Rheumatol."},{"key":"37835_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti, L., Franchi, M., Marchesoni, A. & Corrao, G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 48, 28\u201334 (2018).","journal-title":"Semin Arthritis Rheum."},{"key":"37835_CR5","doi-asserted-by":"crossref","unstructured":"Azuaga, A. B., Ram\u00edrez, J. & Ca\u00f1ete, J. D. Psoriatic arthritis: pathogenesis and targeted therapies. Int. J. Mol. Sci. 24. (2023).","DOI":"10.3390\/ijms24054901"},{"key":"37835_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","volume":"81","author":"AA Deodhar","year":"2022","unstructured":"Deodhar, A. A. et al. Safety of Ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Ann. Rheum. Dis. 81, 944 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/art.41716","volume":"73","author":"LC Coates","year":"2021","unstructured":"Coates, L. C. et al. Withdrawing Ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a Randomized, Double-Blind withdrawal study. Arthritis Rheumatol. 73, 1663\u20131672 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"37835_CR8","doi-asserted-by":"crossref","unstructured":"Reich, A. et al. Real-world evidence for Ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016\u20132021. J. Dermatolog Treat. 34. (2023).","DOI":"10.1080\/09546634.2022.2160196"},{"key":"37835_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash, P. et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389, 2317\u20132327 (2017).","journal-title":"Lancet"},{"key":"37835_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease, P. J. et al. A head-to-head comparison of the efficacy and safety of Ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 79, 123\u2013131 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease, P. J. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 76, 79\u201387 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR12","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jpm14070716","volume":"14","author":"E Bellis","year":"2024","unstructured":"Bellis, E. et al. Retention rate of Ixekizumab in psoriatic arthritis: A Real-World study. J. Pers. Med. 14, 716 (2024).","journal-title":"J. Pers. Med."},{"key":"37835_CR13","doi-asserted-by":"crossref","unstructured":"Bra\u00f1a, I. et al. Treatment retention and safety of Ixekizumab in psoriatic arthritis: A real life Single-Center experience. J. Clin. Med. ; 12. (2023).","DOI":"10.3390\/jcm12020467"},{"key":"37835_CR14","doi-asserted-by":"crossref","unstructured":"Chimenti, M. S. et al. Effectiveness of Ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the gruppo Italiano studio early arthritis multicentric prospective registry. Clin. Exp. Rheumatol. 42 (11), 2221\u20132228 (2024).","DOI":"10.55563\/clinexprheumatol\/udiit0"},{"key":"37835_CR15","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"37835_CR16","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce, B. & Fries, J. F. The health assessment questionnaire (HAQ). Clin. Exp. Rheumatol. 23, S14\u2013S18 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"37835_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels, M. M., Aletaha, D., Alasti, F. & Smolen, J. S. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann. Rheum. Dis. 75, 811\u2013818 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/03009742.2023.2213509","volume":"53","author":"CAJ Michielsens","year":"2024","unstructured":"Michielsens, C. A. J. et al. Construct validity of bath ankylosing spondylitis disease activity index (BASDAI) and ankylosing spondylitis disease activity score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study. Scand. J. Rheumatol. 53, 180\u2013187 (2024).","journal-title":"Scand. J. Rheumatol."},{"key":"37835_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1136\/rmdopen-2019-001002","volume":"5","author":"LC Coates","year":"2019","unstructured":"Coates, L. C. et al. Original article: measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open. 5, 1002 (2019).","journal-title":"RMD Open."},{"key":"37835_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 18, 465\u2013479 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"37835_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with Pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83, 706 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/CM9.0000000000002646","volume":"136","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese registry of psoriatic arthritis (CREPAR). Chin. Med. J. (Engl). 136, 951 (2023).","journal-title":"Chin. Med. J. (Engl)"},{"key":"37835_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley, G. S. et al. A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 48, 263\u2013273 (2018).","journal-title":"Semin Arthritis Rheum."},{"key":"37835_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","volume":"51","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy, D., Jadon, D. R., Van den Bosch, F., Mease, P. J. & Gladman, D. D. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 51, 880\u2013887 (2021).","journal-title":"Semin Arthritis Rheum."},{"key":"37835_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.semarthrit.2018.03.002","volume":"48","author":"V Chandran","year":"2018","unstructured":"Chandran, V., Stecher, L., Farewell, V. & Gladman, D. D. Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and\/or row? Semin Arthritis Rheum. 48, 430\u2013435 (2018).","journal-title":"Semin Arthritis Rheum."},{"key":"37835_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","volume":"7","author":"A Kumthekar","year":"2020","unstructured":"Kumthekar, A. & Ogdie, A. Obesity and psoriatic arthritis: A narrative review. Rheumatol. Ther. 7, 447 (2020).","journal-title":"Rheumatol. Ther."},{"key":"37835_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/14712598.2021.1849133","volume":"21","author":"G Caldarola","year":"2021","unstructured":"Caldarola, G. et al. Comparison of short- and long-term effectiveness of Ixekizumab and Secukinumab in real-world practice. Expert Opin. Biol. Ther. 21, 279\u2013286 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"37835_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3714","volume":"100","author":"S Sherman","year":"2020","unstructured":"Sherman, S. et al. Ixekizumab survival in heavily pretreated patients with psoriasis: A Two-year Single-centre retrospective study. Acta Derm Venereol. 100, 1\u20135 (2020).","journal-title":"Acta Derm Venereol."},{"key":"37835_CR29","doi-asserted-by":"publisher","first-page":"e14066","DOI":"10.1111\/dth.14066","volume":"33","author":"R Rivera","year":"2020","unstructured":"Rivera, R. et al. The effectiveness and safety of Ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study. Dermatol. Ther. 33, e14066 (2020).","journal-title":"Dermatol. Ther."},{"key":"37835_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40257-019-00490-2","volume":"21","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi, A. et al. Ixekizumab effectiveness and safety in the treatment of Moderate-to-Severe plaque psoriasis: A Multicenter, retrospective observational study. Am. J. Clin. Dermatol. 21, 441\u2013447 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"37835_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jdv.15288","volume":"33","author":"G Deza","year":"2019","unstructured":"Deza, G. et al. Initial results of Ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J. Eur. Acad. Dermatol. Venereol. 33, 553\u2013559 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"37835_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.adengl.2019.06.004","volume":"110","author":"J Magdaleno-Tapial","year":"2019","unstructured":"Magdaleno-Tapial, J. et al. Efficacy and safety of Ixekizumab in a Real-Life practice: A retrospective bicentric study. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 110, 585\u2013589 (2019).","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"37835_CR33","doi-asserted-by":"publisher","first-page":"1184028","DOI":"10.3389\/fmed.2023.1184028","volume":"10","author":"W Tillett","year":"2023","unstructured":"Tillett, W. et al. Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort. Front. Med. (Lausanne). 10, 1184028 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"37835_CR34","doi-asserted-by":"crossref","unstructured":"Philip, A. K., Christopher, H. & Ritchlin, T. Psoriatic arthritis and burden of disease: patient perspectives from the Population-Based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol. Ther. 3. (2016).","DOI":"10.1007\/s40744-016-0029-z"},{"key":"37835_CR35","doi-asserted-by":"publisher","first-page":"105534","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh, J. A. et al. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the united States and Europe. Joint Bone Spine. 90, 105534 (2023).","journal-title":"Joint Bone Spine"},{"issue":"5","key":"37835_CR36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s13555-023-00917-z","volume":"13","author":"F Bellinato","year":"2023","unstructured":"Bellinato, F., Gisondi, P., Fassio, A. & Girolomoni, G. Central pain sensitization in patients with chronic plaque psoriasis. Dermatol. Ther. (Heidelb). 13 (5), 1149\u20131156 (2023).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"37835_CR37","doi-asserted-by":"crossref","unstructured":"Jiang, X. et al. Interleukin-17 as a potential therapeutic target for chronic pain. 13, 999407 (2022).","DOI":"10.3389\/fimmu.2022.999407"},{"key":"37835_CR38","doi-asserted-by":"crossref","unstructured":"Deodhar, A. et al. The effect of Ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther. Adv. Musculoskelet. Dis. 15. (2023).","DOI":"10.1177\/1759720X231189005"},{"key":"37835_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","volume":"14","author":"J Feld","year":"2018","unstructured":"Feld, J., Chandran, V., Haroon, N., Inman, R. & Gladman, D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat. Rev. Rheumatol. 14, 363\u2013371 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"37835_CR40","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","volume":"11","author":"M Schmitt-Egenolf","year":"2021","unstructured":"Schmitt-Egenolf, M. et al. Drug persistence of biologic treatments in psoriasis: A Swedish National population study. Dermatol. Ther. (Heidelb). 11, 2107 (2021).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"37835_CR41","doi-asserted-by":"crossref","unstructured":"Lockshin, B. et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona psoriasis registry. Dermatol. Ther. 34. (2021).","DOI":"10.1111\/dth.14808"},{"key":"37835_CR42","doi-asserted-by":"publisher","first-page":"S420","DOI":"10.1016\/j.jval.2020.08.136","volume":"23","author":"M Kemula","year":"2020","unstructured":"Kemula, M., Morand, F., De Nascimento, J. & Sohrt, A. PBI58 persistence of treatment with biologics for patients with psoriasis: an analysis of a French prescription database. Value Health. 23, S420 (2020).","journal-title":"Value Health"},{"key":"37835_CR43","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","volume":"39","author":"C Leonardi","year":"2022","unstructured":"Leonardi, C. et al. Real-World biologic Adherence, Persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan\u00ae databases. Adv. Ther. 39, 3214\u20133224 (2022).","journal-title":"Adv. Ther."},{"key":"37835_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2147\/PPA.S233993","volume":"14","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt, A. et al. Comparison of Real-World treatment patterns among psoriasis patients treated with Ixekizumab or adalimumab. Patient Prefer Adherence. 14, 517\u2013527 (2020).","journal-title":"Patient Prefer Adherence"},{"key":"37835_CR45","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13555-021-00627-4","volume":"11","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt, A. et al. Comparison of Real-World treatment patterns among Biologic-Experienced patients with psoriasis treated with Ixekizumab or Secukinumab over 18 months. Dermatol. Ther. (Heidelb). 11, 2133\u20132145 (2021).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"37835_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt, A. et al. A head-to-head comparison of Ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br. J. Dermatol. 182, 1348\u20131358 (2020).","journal-title":"Br. J. Dermatol."},{"key":"37835_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","volume":"18","author":"S Tarannum","year":"2022","unstructured":"Tarannum, S. et al. Sex- and gender-related differences in psoriatic arthritis. Nat. Rev. Rheumatol. 18, 513\u2013526 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"37835_CR48","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","volume":"9","author":"L Eder","year":"2022","unstructured":"Eder, L. et al. Responses to Ixekizumab in male and female patients with psoriatic arthritis: results from two Randomized, phase 3 clinical trials. Rheumatol. Ther. 9, 919 (2022).","journal-title":"Rheumatol. Ther."},{"key":"37835_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/bja\/aet127","volume":"111","author":"EJ Bartley","year":"2013","unstructured":"Bartley, E. J. & Fillingim, R. B. Sex differences in pain: a brief review of clinical and experimental findings. Br. J. Anaesth. 111, 52\u201360 (2013).","journal-title":"Br. J. Anaesth."},{"key":"37835_CR50","doi-asserted-by":"crossref","unstructured":"Cabo-Meseguer, A., Cerd\u00e1-Olmedo, G. & Trillo-Mata, J. L. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Med. Clin. 149 2017 441\u2013448 .","DOI":"10.1016\/j.medcle.2017.10.011"},{"key":"37835_CR51","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1136\/annrheumdis-2020-217251","volume":"81","author":"I Pantano","year":"2022","unstructured":"Pantano, I. et al. Secukinumab efficacy in patients with PsA is not dependent on patients\u2019 body mass index. Ann. Rheum. Dis. 81, e42\u2013e42 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"37835_CR52","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1080\/09546634.2020.1853023","volume":"33","author":"M Shahriari","year":"2022","unstructured":"Shahriari, M. et al. Disease response and patient-reported outcomes among initiators of Ixekizumab. J. Dermatolog Treat. 33, 1538\u20131546 (2022).","journal-title":"J. Dermatolog Treat."},{"key":"37835_CR53","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/jdv.14252","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich, K. et al. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1196\u20131207 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"37835_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-023-03257-7","volume":"26","author":"A Deodhar","year":"2024","unstructured":"Deodhar, A. et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res. Ther. 26, 1\u201316 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"37835_CR55","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan, S. R. et al. A Randomized, Double-Blind, Placebo-Controlled phase 2 study of brodalumab in patients with Moderate-to-Severe crohn\u2019s disease. Am. J. Gastroenterol. 111, 1599\u20131607 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"37835_CR56","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693 (2012).","journal-title":"Gut"},{"key":"37835_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith, M. K. et al. Crohn\u2019s-like disease in a patient exposed to anti-Interleukin-17 Blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 19, 162 (2019).","journal-title":"BMC Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37835-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:29:35Z","timestamp":1781634575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37835-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37835"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37835-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Siena (Reference No. Rhelabus 22271). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"7051"}}